Jeremy Grantham Gritstone Bio, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$2.57 - $4.22 $39,835 - $65,409	-15,500 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.63 - $8.09 $3,419 - $10,517	1,300 Added 9.15%	15,500 $41,000
Q2 2020 Aug 13, 2020	BUY	$5.69 - $8.17 $80,798 - $116,014	14,200 New	14,200 $94,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.